Paradigm4 has signed an agreement with 54Gene allowing the latter to use the former’s Reveal Biobank App to explore, characterise and query 54Gene’s African Health Information Ecosystem, which is a curated data source of clinical phenotype and genetic information from which insights can be generated to assist the development of treatments and diagnostics.
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
Paradigm4, an integrated scientific data analytics company, has launched flexFS, its elastic cloud file system for flexible and more resource-efficient data storage and scalable computing.
